Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Frequently asked questions
What sector does Unity Biotechnology, Inc. (UNBX) operate in?
Unity Biotechnology, Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is Unity Biotechnology, Inc. (UNBX) current stock price?
As of the latest data, Unity Biotechnology, Inc. stock price is $0.06, with a previous close of $0.06.
What is Unity Biotechnology, Inc. (UNBX) current market capitalization?
Unity Biotechnology, Inc. market cap is approximately 965.60 thousand.
Does Unity Biotechnology, Inc. (UNBX) pay dividends?
No. Unity Biotechnology, Inc. does not pay a dividend.
What is Unity Biotechnology, Inc. (UNBX) beta (volatility) score?
Unity Biotechnology, Inc. has a beta of 2.071, indicating very high volatility compared to the market.
